Share on StockTwits

Equities researchers at FBR Capital Markets decreased their price objective on shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) from $17.00 to $16.00 in a research report issued on Tuesday. The firm currently has an “outperform” rating on the stock. FBR Capital Markets’ price objective would suggest a potential upside of 88.46% from the stock’s previous close.

In other Raptor Pharmaceutical Corp. news, CFO Georgia Erbez bought 16,100 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, May 13th. The stock was purchased at an average cost of $7.90 per share, for a total transaction of $127,190.00. Following the completion of the acquisition, the chief financial officer now directly owns 16,100 shares in the company, valued at approximately $127,190. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

Several other analysts have also recently commented on the stock. Analysts at Leerink Swann cut their price target on shares of Raptor Pharmaceutical Corp. from $24.00 to $18.00 in a research note on Friday, May 9th. They now have an “outperform” rating on the stock. Analysts at Wedbush cut their price target on shares of Raptor Pharmaceutical Corp. from $10.00 to $7.00 in a research note on Tuesday, May 6th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $14.93.

Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) traded up 1.59% during mid-day trading on Tuesday, hitting $8.625. 341,149 shares of the company’s stock traded hands. Raptor Pharmaceutical Corp. has a 1-year low of $6.69 and a 1-year high of $17.72. The stock’s 50-day moving average is $8.20 and its 200-day moving average is $12.45. The company’s market cap is $540.1 million.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last announced its earnings results on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by $0.03. The company had revenue of $12.10 million for the quarter, compared to the consensus estimate of $11.81 million. The company’s quarterly revenue was up 120999900.0% on a year-over-year basis. Analysts expect that Raptor Pharmaceutical Corp. will post $-0.72 EPS for the current fiscal year.

Raptor Pharmaceuticals Corp. (NASDAQ:RPTP), formerly TorreyPines Therapeutics, Inc, is an early development-stage Company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.